Loading...
Acquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?
The recent AstraZeneca takeover bid from Pfizer puts pharmaceutical R&D once again on the public agenda. Three pertinent questions are (a) what can be expected from this acquisition, (b) what are the implications for the UK economy and science base, and (c) whether such a deal should go ahead. A...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4203995/ https://ncbi.nlm.nih.gov/pubmed/25346596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40290-014-0066-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|